Dry Eye

Resources and strategies that can be used to help educate patients about dry eye disease and optimize adherence to therapy.

Oculis reported positive data from two of its clinical proof-of-concept phase 2 trials for OCS-02, a novel topical anti-TNF alpha antibody fragment candidate, for the treatment of dry eye disease and acute anterior uveitis.

Criteria that would prompt further evaluation for dry eye disease and the types of tests used to work-up and accurately diagnose the condition.

Eye care professionals explain the impact of unstable tear film and untreated dry eye disease on patient quality of life.

Joseph Grieco, PhD, notes that treatment fills a gap for patients who are unresponsive to the standard treatments for noninfectious keratitis.

Christopher Starr, MD, discusses key points from his virtual ARVO 2021 presentation regarding dry eye disease flares, including a rapid readout assessment of 10 years' worth of world literature to analyze studies in which the inflammatory disease's condition are categorized.

Seth Miller, clinical operations manager at Ora Inc., discusses the relationship between the symptoms of dry eye and aging, based on his ARVO 2021 presentation.

Jeffrey Gemi, MD, Ora Inc., speaks on the highlights from his presentation comparing Schirmer's test with other clinical outcomes in dry eye.

The impact of autoimmune and systemic diseases as well as environmental triggers on the development of dry eye disease.

A panel of ophthalmologists and optometrists begin a discussion on the management of dry eye disease by defining the condition and highlighting common symptoms.

ThermaMEDx has unveiled a self-heating, pre-moistened, disposable, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction.

Bausch + Lomb and Novaliq GmbH have announced statistically significant topline data from the first phase 3 trial analyzing the investigational drug NOV03 as a first-in-class eye drop to treat dry eye disease associated with MGD.

Product offers improvement in objective dry eye disease measures, providing relief.

Phase 2 trial of 0.3% minocycline microparticle suspension shows promise in dry eye diseases associated with Inflamed meibomian gland dysfunction

Cynthia Matossian, MD, FACS, ABES, explores the tie between mask wear and dry eye, causes behind a growing number of MGD cases, and offers mask safety tips for patient treatment.

RegeneRx Biopharmaceuticals announces that its ARISE-3 Phase 3 clinical trial evaluating RGN-259 eyedrops did not meet its primary outcome measures.

Peter J. Polack, MD, FACS, of Ocala Eye, discusses how proper patient education and nutrition have been key to managing an increase in dry eye patients during the pandemic.

The FDA has accepted Oyster Point Pharma's New Drug Application (NDA) for its OC-01 (varenicline) nasal spray to treat dry eye disease.

Autologous serum eye drops and blood products offer hope to patients.

Growing patient pool is driving clinical trial investment.

Ocular symptoms in COVID-19 patients may be more common than previously thought — with sore eyes a significant sign of disease.

Sunita Radhakrishnan, MD, in a presentation at the 25th annual Glaucoma Symposium at the Glaucoma 360 virtual annual event, noted that concomitant treatment of both glaucoma and dry eye is key.

Cynthia Matossian, MD, FACS, ABES, continues her discussion on MGD treatment by explaining why it's important for patients to understand that MGD and dry eye are lifelong, chronic conditions requiring regular maintenance and monitoring.

New options open possibilities for treatment, resulting in better outcomes for patients.

Study supports preoperative ocular surface optimization with artificial tears.

A novel ocular corticosteroid is offering hope of quick results for patients.

In light of an unprecedented year filled with technological advancements and pivots, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2021.

Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.